IP Library Granted Patent US 6,987,091
Granted Patent B2
US 6,987,091 · App. 10/301,514 · Granted Jan 17, 2006

Sir2 products and activities

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,987,091
App. No.
10/301,514
Granted
Jan 17, 2006
Kind
B2
Abstract

A novel compound, 2′/3′-O-acetyl-ADP-ribose, is provided. The compound is a mixture of the 2′ and 3′ regioisomers of O-acetyl-ADP ribose, and is formed nonenzymatically from 2′-O-acetyl-ADP-ribose, which is the newly discovered product of the reaction of Sir2 enzymes with acetylated peptides and NAD + . Analogs of 2′/3′-O-acetyl-ADP-ribose are also provided. Additionally, methods of preparing 2′/3′-O-acetyl-ADP-ribose, methods of determining whether a test compound is an inhibitor of a Sir2 enzyme, methods of detecting Sir2 activity in a composition, methods of deacetylating an acetylated peptide, and methods of inhibiting the deacetylation of an acetylated peptide are provided. Prodrugs of 2′/3′-O-acetyl-ADP-ribose are also provided.

Claims (10)

1. A purified mixture of 2′/3′-O-acetyl-ADP-ribose in equilibrium.

2. An analog of 2′-O-acetyl-ADP-ribose or 3′-O-acetyl-ADP-ribose exhibiting increased stability in cells, wherein the 2′-O-acetyl-ADP-ribose and the 3′-O-acetyl-ADP-ribose both comprise an acetate group with an ester oxygen, and an oxygen between two phosphorous atoms.

3. The analog of claim 2 , wherein a CF 2 , a NH, or an S replaces the ester oxygen or the oxygen between two phosphorous atoms.

4. The analog of claim 3 , wherein a CF 2 or NH, or a S independently replaces the ester oxygen and the oxygen between two phosphorous atoms.

5. The analog of claim 3 , wherein a CF 2 , a NH, or an S replaces the ester oxygen.

6. The analog of claim 3 , wherein a CF 2 replaces the ester oxygen or the oxygen between two phosphorous atoms, or wherein a CF 2 replaces both the ester oxygen and the oxygen between two phosphorous atoms.

7. The analog of claim 3 , wherein a CF 2 replaces the ester oxygen.

8. The mixture of claim 1 in an aqueous composition having a solute, excluding salts, that is at least 50% 2′/3′-O-acetyl-ADP-ribose in equilibrium.

9. The mixture of claim 1 in an aqueous composition having a solute, excluding salts, that is at least 75% 2′/3′-O-acetyl-ADP-ribose in equilibrium.

10. The mixture of claim 1 in an aqueous composition having a solute, excluding salts, that is at least 90% 2′/3′-O-acetyl-ADP-ribose in equilibrium.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jun 10, 2024
From: ALBERT EINSTEIN COLLEGE OF MEDICINE
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 067676/0607 →
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CHANGE OF NAME Recorded Oct 19, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036888/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036855/0743 →